Oculogica provides eye-tracking technology that detects proper brain functioning. Oculogica’s EyeBox CNS is authorized by the FDA as an aid in the diagnosis of concussion. Its technology detects weaknesses of the specific cranial nerves that move the eye, and the signature of palsies in any given patient informs regarding the location and nature of their pathology. Its solution requires no baseline data or individual calibration, so the results cannot be influenced by a patient's will. The company operates in the Neurology sector with additional focus on Healthcare IT and Eye Tracking. Its business model centers on Healthcare. Founded in 2013, headquartered in New York City, United States. The company has raised $22.0M at the Series B stage. Backed by investors including TitletownTech, HHS, Colle Capital, Sofia Fund, Lateral Capital and others.
Oculogica
Series BOculogica provides eye-tracking technology that detects proper brain functioning. Oculogica’s EyeBox CNS is authorized by the FDA as an aid in the diagnosis of concussion. Its technology detects weaknesses of the specific cranial nerves that move the eye, and the signature of palsies in any given patient informs regarding the location and nature of their pathology. Its solution requires no baseline data or…
About
Business model
Eye Tracking > Applications > Healthcare,
Healthcare IT > Provider > Clinical Operations > Decision Support > Diagnosis > Diagnostics and Assessment Tests > Cognitive Assesment > Eye tracking,
Neurology > Medical Devices > Screening Devices > Eye Tracking
Institutional investors
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Investor directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.